| DX126-262 / Hangzhou DAC Biotech |
DX126-262-002Breast, CTR20211871: A Phase II clinical study to evaluate the efficacy and safety of a recombinant humanized anti-HER2 monoclonal antibody-Tub114 conjugate (DX126-262) in patients with HER2-positive unresectable locally advanced or recurrent metastatic breast cancer |
|
|
| Ongoing | 2 | 662 | China | DX126-262 - Hangzhou DAC Biotech | Hangzhou Duoxi Biotechnology Co., Ltd | HER2-positive unresectable locally advanced or recurrent metastatic breast cancer | | | | |
DX126-262-002NSCLC, CTR20222171: A Phase Ib/II study to evaluate the safety, efficacy, and pharmacokinetics of a recombinant humanized anti-HER2 monoclonal antibody-Tub114 conjugate (DX126-262) in patients with HER2-positive or HER2 mutated unresectable locally advanced or metastatic non |
|
|
| Ongoing | 1b/2 | | China | DX126-262 - Hangzhou DAC Biotech | Hangzhou Duoxi Biotechnology Co., Ltd | HER2-positive or HER2 gene mutation with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) | | | | |
CTR20220870: A Phase Ib/II clinical study to evaluate the safety, efficacy and pharmacokinetics of DX126-262 in patients with HER2-overexpressing unresectable locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) |
|
|
| Recruiting | 1b/2 | 433 | China | DX126-262 - Hangzhou DAC Biotech | Hangzhou Duoxi Biotechnology Co., Ltd. | Unresectable locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) overexpressing human epidermal growth factor receptor 2 (HER2) | | | | |
CTR20221490: A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of DX126-262 in Subjects With Unresectable Locally Advanced or Recurrent Metastatic Urothelial Carcinoma With HER2 Overexpression. |
|
|
| Ongoing | 1b/2 | 126 | China | DX126-262 - Hangzhou DAC Biotech | Hangzhou Duoxi Biotechnology Co., Ltd | HER2 overexpressing unresectable locally advanced or recurrent metastatic urothelial carcinoma | | | | |
